Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?
List view / Grid view
Why has the pharma industry and its talents lost interest in developing new antibiotics?
Drug manufacturers are increasingly adopting continuous bioprocessing to manufacture biologics as efficiently as possible. This is being driven by a need to reduce production costs and prices of pharmaceutical products. Furthermore, the FDA has stated its support for the implementation of continuous bioprocessing. A key consequence of continuous bioprocessing is…
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
2 October 2019 | By SUEZ – Ozonia® Ozone Systems
This webinar guides you through efficiency gains with TOC for cleaning validation. We call it a ‘beginner’s guide’, but the session will benefit long-time TOC users as well as those new to using TOC for cleaning validation.
The impact of new and alternative monitoring technologies on labor costs in the laboratory and in manufacturing can be significant.
Liquid chromatography mass spectrometry (LC-MS) is a highly accurate and sensitive platform used in biopharmaceutical research and development.
The Jynneos live, non-replicating vaccination for smallpox and monkeypox has been approved by the FDA for high-risk patients.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
19 September 2019 | By SUEZ
This webinar will present how to easily evaluate "fitness for purpose" of a TOC instrument for compendial water and cleaning validation applications based on USP and ICH Q2(R1).
The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
The EMA has announced it is drafting guidance on how to avoid the presence of nitrosamines, a probable carcinogenic ingredient, in drugs.
CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany.
The EMA will assess the marketing authorisation for the medication to see whether it is a cause of skin cancer in patients.
Medicinal products typically cannot be manufactured without using excipients. Here, Dave Elder and Fabio Faïs discuss factors for excipient selection and the importance of defined allowable limits to ensure continued product safety.
Transforming a formulation into a successful solid dose product is a complex process that involves many considerations. Given the ever-growing demand for increased tablet quantities and the goal of reducing time to market, Rob Blanchard explains how the pressure is on manufacturers to find innovative processes to improve production efficiency.